Eyenovia Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Eyenovia hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.2%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$0.60
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

New Forecasts: Here's What One Analyst Thinks The Future Holds For Eyenovia, Inc. (NASDAQ:EYEN)

Apr 03

Earnings Beat: Eyenovia, Inc. (NASDAQ:EYEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Mar 31

Eyenovia: I Can See You Better - Now

Mar 04

Eyenovia: Reassessing After The FDA Moves The Goalposts

Nov 23

Eyenovia: FDA Setback Is Big Opportunity For Investors

Nov 08

Eyenovia: Can You See Me Now?

Oct 21

Is Eyenovia (NASDAQ:EYEN) A Risky Investment?

Sep 16

Eyenovia updates on late-stage program for presbyopia therapy

Jun 15

Eyenovia: Recent MicroLine Data, October MydCombi PDUFA Date Bode Well For Value Creation

Jun 02

Eyenovia announces new $25M credit facility with Silicon Valley Bank

May 10

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von EYEN in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von EYEN gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Eyenovia Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von EYEN im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (EYEN)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.7%
Branchendurchschnitt (Pharmaceuticals)	2.2%
Analystenprognose in 3 Jahren (EYEN)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von EYEN im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von EYEN im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von EYEN, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da EYEN keine Ausschüttungen gemeldet hat.

Eyenovia Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Consensus revenue estimates decrease by 32%, EPS upgraded

Eyenovia, Inc. to Report Q1, 2024 Results on May 15, 2024

Eyenovia, Inc., Annual General Meeting, Jun 12, 2024

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension

New major risk - Share price stability

Eyenovia, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 27%

Consensus revenue estimates increase by 32%

Eyenovia, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Price target decreased by 8.6% to US$10.67

Consensus revenue estimates increase by 33%

Consensus revenue estimates increase by 33%

Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 54%

New minor risk - Share price stability

High number of new directors

Eyenovia, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production

Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?

Eyenovia, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?

Insider recently bought US$234k worth of stock

Eyenovia, Inc., Annual General Meeting, Jun 27, 2023

Eyenovia, Inc. Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis

Eyenovia, Inc. to Report Q1, 2023 Results on May 11, 2023

Co-Founder recently sold US$300k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

No longer forecast to breakeven

No longer forecast to breakeven

Eyenovia, Inc. Showcases Microdose Array Print (MAP™) Technology At CES 2023 in Las Vegas

Eyenovia, Inc. Announces Positive Results from a Research Study

Forecast to breakeven in 2025

High number of new directors

Eyenovia Aims to Revolutionize Ophthalmology Devices with Microdose Array Print (Map) Technology

Eyenovia, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation

Eyenovia, Inc. Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President, Effective January 1, 2023 and Julia Haller Steps Down from its Board of Directors

Price target decreased to US$14.33

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.21 loss in 3Q 2021)

Eyenovia, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?

Eyenovia, Inc Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia

Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential

Eyenovia, Inc. Announces Retirement of Ken Lee as Lead Independent Director

Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First

First half 2022 earnings released

Eyenovia, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Eyenovia, Inc. Announces Board Changes

Eyenovia names Michael Rowe as new CEO

Eyenovia Appoints Bren Kern as SVP of Manufacturing and Operations

Eyenovia, Inc. Announces Executive Changes

Insider recently bought US$165k worth of stock

Eyenovia Inc. Announces Transition of Sean Ianchulev from CEO to Non-Executive Chairman of the Board

Price target increased to US$17.50

Insider recently bought US$113k worth of stock

Eyenovia, Inc. to Report Q1, 2022 Results on May 12, 2022

Eyenovia, Inc., Annual General Meeting, Jun 16, 2022

Less than half of directors are independent

Consensus revenue estimates increase by 41%

New Forecasts: Here's What One Analyst Thinks The Future Holds For Eyenovia, Inc. (NASDAQ:EYEN)

Earnings Beat: Eyenovia, Inc. (NASDAQ:EYEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Eyenovia, Inc. to Report Q4, 2021 Results on Mar 28, 2022

Eyenovia: I Can See You Better - Now

Insider recently bought US$144k worth of stock

Insider recently bought US$107k worth of stock

Eyenovia Concludes Type A Meeting with FDA Related to Mydcombi NDA Resubmission

Eyenovia Announces Changes to Board of Directors

Insider recently bought US$345k worth of stock

Eyenovia: Reassessing After The FDA Moves The Goalposts

Insider recently bought US$361k worth of stock

Eyenovia: FDA Setback Is Big Opportunity For Investors

Insider recently bought US$535k worth of stock